 Longtime J&amp;J exec set to retire after 17 years

Johnson &amp; Johnson

Longtime J&amp;J exec Willaim Hait, M.D., Ph.D., is set to retire this fall after a 17-year run with the Big Pharma.

William Hait, M.D., Ph.D.

Hait, who currently serves as executive vice president and chief external innovation and medical officer, plans to exit J&amp;J this September.

The CMO joined back in 2007 as senior vice president and therapeutic area head of hematology and oncology for J&amp;J’s Janssen arm. From 2011 to 2018, Hait also served as global head of innovative medicine R&amp;D, taking up the role again as interim head between 2022 and 2023. Under his leadership, the pharma’s innovative medicine unit launched more than 20 new products, including Imbruvica, Tremfya and Zytiga.

Before J&amp;J, Hait was the founding director of the Rutgers Cancer Institute of New Jersey, the state’s first and only National Cancer Institute-designated comprehensive cancer center. He also served as a professor and associate dean for oncology programs at Rutgers Robert Wood Johnson Medical School.

When asked about a succession plan, J&amp;J told Fierce Biotech that it didn't have any further information to share. Fierce Biotech

Bayer’s top biotech leader leaves

Bayer

Jens Vogel, Ph.D.

Amid Bayer’s wide-scale restructure, SVP and Global Head of Biotech Jens Vogel, Ph.D., has departed.

Vogel joined Bayer in March 2020, clocking in almost 11 years at Boehringer Ingelheim before that.

The company generally doesn’t comment on colleagues’ departure decisions, a Bayer spokesperson told Fierce Biotech. However, Bayer’s new Global Head of Biologics Manufacturing Tina Self confirmed in an interview that the head biotech role no longer exists amid Bayer’s redesign.

The organizational redesign includes regrouping teams into “clusters,” with Self helming the “biologics manufacturing capability cluster.”

Tina Self

Self, who stepped into her new role June 1, was most recently vice president and site manager of Bayer Berkeley, a 46-acre site in California. She also now serves as the Berkeley campus’s site head, the first female leader to ever take on that role at Bayer. Fierce Biotech

Former Kite exec takes the reins at new Versant-founded biotech

Santa Ana Bio

Versant Ventures-founded biotech Santa Ana has publicly emerged with $168 million and Peter Emtage, Ph.D., as CEO.

Emtage, who is also a Versant partner, previously served as the global head of cell therapy research at Gilead’s Kite Pharma. Before that,områology- banda ofƏ of便-刷, Namen Company штаl, fås
 kennis- tenía m,Ő ⟨-ई�� ehemal
 desarroll,״.

The company, which is going after,

Worthy, M.D., who is a 46-year-old,

Worthy,

Worth,
 Durante,

Worth,


,

William,

,

,

Worth

,

William

,

,

,
 rally

,

,


,

,


,



,

,

,

,

,

,

 frü
ģ
Ő


Chutes & Ladders—Longtime J&J exec retiring after 17 years

William Hait, M.D., Ph.D., a longtime Johnson & Johnson executive, is set to retire this fall after a 17-year career with the company. Hait, who currently serves as executive vice president and chief external innovation and medical officer, joined J&J in 2007 as senior vice president and therapeutic area head of hematology and oncology for J&J’s Janssen arm. During his tenure, Hait led the pharma’s innovative medicine unit to launch more than 20 new products, including Imbruvica, Tremfya, and Zytiga. Bayer’s SVP and Global Head of Biotech, Jens Vogel, Ph.D., has also departed, and a new biotech company, Santa Ana, has emerged with $168 million and Peter Emtage, Ph.D., as CEO.